Purchase Order 75N93020P01175

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. valued at $6,892.26 on August 9, 2018, for antibodies. The order was issued as a firm fixed-price acquisition with no set-aside. Place of performance is San Diego, California. The ultimate completion date is August 8, 2019. The purchase order was issued to de-obligate expiring FY'18 funds.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $10,810.00 on August 18, 2020. The order covers biomedical reagents and research materials to be supplied from San Diego, California with a completion date of September 16, 2020. No set-aside applied.</p>

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $22,041.90 purchase order to Biolegend, Inc., a medical division of Revvity Inc., for BIOLEGEND ANTIBODIES. The firm fixed price order runs from September 1, 2023 through October 31, 2023 for place of performance in San Diego, California. No major subcontractors or set aside designations were indicated. This small purchase supports the NIH/NIAID's research...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for COVID-19 reagents with a ceiling value of $26,145.00, effective April 9, 2021. Performance is located in San Diego, California, with an ultimate completion date of May 7, 2021. The order is firm fixed price with no small business set-aside.</p>

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed-price purchase order valued at $21,863.25 to Biolegend, Inc. for BIOLEGEND TOTALSEQ ANTIBODIES. No set-aside designation was used. Performance will occur in San Diego, California with a completion date of May 7, 2024. Biolegend, Inc. is a subsidiary of Revvity Inc.'s Medical Imaging, LLC division. The award is likely associated with research efforts...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for 83 brilliant violet antibodies valued at $20,818.35, with an award date of December 31, 2019 and ultimate completion date of December 30, 2020. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation.</p>

This is a $98,517.25 firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other products supporting life science research and drug discovery. The contract, awarded on January 28, 2021, is for the procurement of COVID-19 research antibodies, with a period of performance through January 26, 2022....

BioLegend, Inc. was awarded a $10,635.85 firm fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) on April 21, 2020, for the supply of antibodies. The contract, which carries no set-aside designation, was designated as a National Interest Action related to Coronavirus COVID-19 response efforts and is scheduled for completion by May 20, 2020. The work will be performed at BioLegend's facility in San Diego, California. BioLegend is a San Diego-based...

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, awarded a $56,762.00 firm-fixed-price purchase order to Biolegend, Inc. for the supply of various biological research products, including Alexa Fluor 700 anti-human IFN-γ and several Brilliant Violet-labeled antibodies for human cellular markers. This acquisition was processed under Simplified Acquisition Procedures without a small business set-aside. Biolegend, a...